HLB "Lenvatinib, Oral Presentation of Lung Cancer Clinical Results at World Lung Cancer Conference... Reconfirmation of Disease Control Effect"

[Asia Economy Reporter Hyunseok Yoo] HL Biotech announced on the 2nd that two clinical trial results on the combination therapy of rivoceranib (Chinese name Apatinib), immune checkpoint inhibitors, and cytotoxic chemotherapy will be presented orally and as posters at the World Conference on Lung Cancer (WCLC2021), held online from the 8th to the 14th.

The World Conference on Lung Cancer is the largest academic conference specializing in lung cancer and other thoracic malignancies, with over 7,000 participants from more than 100 countries worldwide every year, making it a prestigious event.

Oral presentation of the Phase 2 clinical trial results combining rivoceranib and the immune checkpoint inhibitor camrelizumab (PD-1 inhibitor) in 25 non-small cell lung cancer (NSCLC) patients conducted at a specialized lung cancer hospital in Shanghai, China, will be held on the 13th. According to the disclosed abstract, the clinical results showed an objective response rate (ORR) of 40%, disease control rate (DCR) of 92%, and median progression-free survival (mPFS) of 11 months. This demonstrated high efficacy and safety as a first-line treatment for advanced NSCLC.

Results of the combination therapy of rivoceranib, camrelizumab, and cytotoxic chemotherapy albumin-bound paclitaxel in patients with advanced first-line NSCLC will also be presented in poster format. The Phase 2 clinical trial conducted on 8 patients with stage 3-4 NSCLC at a cancer specialty hospital in Hunan, China, showed an ORR of 50% and DCR of 62.5%, proving stable efficacy.

Separately, on August 31, the journal platform ‘Research Square’ published results of a neoadjuvant triple combination therapy of rivoceranib, albumin-bound paclitaxel, and carboplatin in 32 patients with triple-negative breast cancer (TNBC) conducted at the First Affiliated Hospital of Nanjing Medical University, China.

Among the clinical results, complete response (CR) was observed in 7 patients who underwent surgical resection, 23 showed partial response (PR), and 2 had stable disease (SD). Additionally, progressive disease (PD) was zero, confirming that tumor size did not increase in any patient.

The central target lesion decreased from 1.2 cm after the third treatment cycle to 0.9 cm after the final cycle. The researchers suggested in the paper that pre-treatment with these three drugs could produce good effects in TNBC patients whose tumors are too large for immediate surgery.

This content was produced with the assistance of AI translation services.